A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients

Launched by HANLIM PHARM. CO., LTD. · Oct 10, 2017

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Both gender, 19 years ≤ age ≤ 80 years
• • 2. (Bronchitis Severity Score)\* ≥ 5point at Visit 2 (Randomized Visit)
• • 3. Acute bronchitis within 48hr based on Visit 2 (Randomized Visit)
• • 4. Those who can comply with the requirements of clinical trials
• • 5. Written consent voluntarily to participate in this clinical trial
• Exclusion Criteria:
• • 1. Patients with respiratory and systemic infections requiring systemic antibiotic therapy
• • 2. Patients with bleeding tendency
• • 3. Patients who investigators determines to severe respiratory disease that would interfere with study assessment
• • 4. Patients who were treated with oral systemic adrenocortical hormone or immunosuppressive drug within 4 weeks prior to Visit 2
• • 5. Patients who were treated with oral antihistamines, ACE suppressive. or systemic/inhalative glucocorticosteroid within 2 weeks prior to Visit 2